S& P 500 hits all time highs U.S.-Japan trade deal optimism
Investing.com -- Shares of Vimian Group AB (STO:VIMIAN) surged 6.5% following the company’s announcement of its fourth-quarter results, which surpassed consensus expectations.
The company reported this morning that its Q4 revenues beat compiled consensus by 5.9%, with an adjusted EBITA 0.8% above expectations. Vimian’s organic growth notably exceeded forecasts, coming in at 15.0% compared to the consensus of 8.6%.
The Diagnostics segment outperformed despite market challenges, registering a 12.0% organic growth against a predicted decline of 1.9%. This uptick was attributed to recent disease outbreaks, and the company anticipates a return to positive growth by 2025.
The MedTech division also reported growth, with a 4.0% increase in organic sales, buoyed by a 5.0% rise in North America despite a sluggish US surgery market. Performance in Europe and the Asia-Pacific region showed lower but steady growth.
Specialty Pharmaceuticals and Specialized Nutrition significantly contributed to the robust performance of the Spec Pharma division, which saw a 22.0% increase, outpacing the 12.0% consensus. Additionally, the Vet Services sector maintained strong momentum with a 16.0% rise, surpassing the 13.1% market expectations.
The company also highlighted an improvement in cash flow, driven by higher operating profits and better working capital management.
Barclays (LON:BARC) analysts commented on the results, stating, "We expect the organic beat and results ultimately to be taken positively by the market, but we look for more clarity on weaker margins as well as the timeline to a recovery in the US surgery on the call.
We reiterate our EW rating and continue to look for a sustainable improvement in management’s track record of execution."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.